Memogalin (Aripiprazole)

Aripiprazole acts as a partial agonist at dopamine D2 and serotonin 5‑HT1A receptors while blocking serotonin 5‑HT2A receptors. This unique receptor profile balances neurotransmitter activity, helping to reduce psychotic symptoms, stabilise mood, and improve depressive outcomes without fully suppressing dopamine signaling.

The dose of Memogalin is individualized by the prescribing clinician based on the patient’s diagnosis, response, and tolerability. Dosage adjustments may be made during treatment, and patients should follow the prescriber’s specific instructions.

Safety data for aripiprazole in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Memogalin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with many atypical antipsychotics, aripiprazole has a partial agonist profile that may result in a lower incidence of certain side effects such as prolactin elevation. However, individual response varies, and clinicians consider efficacy, tolerability, drug‑interaction potential and patient history when selecting therapy.

Memogalin should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability.

Memogalin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, suicidal thoughts or behaviours, severe hypotension and seizures. Patients should be monitored closely for any of these events, and treatment should be discontinued immediately if they occur.

Memogalin is contraindicated in individuals with known hypersensitivity to aripiprazole or any of its excipients. Caution is advised for patients with uncontrolled cardiovascular disease, severe hepatic impairment, or those taking prohibited drug combinations such as MAO inhibitors.